Ritsinger V, Nyström T, Saleh N, et al. Heart failure is a common complication after acute myocardial infarction in patients with diabetes: A nationwide study in the SWEDEHEART registry. Eur J Prev Cardiol 2020; 27: 1890–1901.
2.
KannelWBMcGeeDL. Diabetes and cardiovascular disease. The Framingham study. JAMA1979; 241: 2035–2038.
3.
FerriniMJohanssonIAboyansV. Heart failure and its complications in patients with diabetes: mounting evidence for a growing burden. Eur J Prev Cardiol2019; 26(2-suppl): 106–113.
4.
RobertsRRogersWJMuellerHS, et al.Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation1991; 83: 422–437.
5.
YusufSPetoRLewisJ, et al.Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis1985; 27: 335–371.
6.
FranzosiMG. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials. Circulation1998; 97(22): 2202–2212.
7.
KennyHCAbelED. Heart failure in type 2 diabetes mellitus: impact of glucose-lowering agents, heart failure therapies, and novel therapeutic strategies. Circ Res2019; 124: 121–141.
8.
ZelnikerTAWiviottSDRazI, et al.Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation2019; 139: 2022–2031.
9.
PerkovicVJardineMJNealB, et al.CREDENCE study investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med2019; 380: 2295–2306.
10.
McMurrayJJVSolomonSDInzucchiSE, et al.DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med2019; 381: 1995–2008.
11.
McNamaraRLChungSCJernbergT, et al.International comparisons of the management of patients with non-ST segment elevation acute myocardial infarction in the United Kingdom, Sweden, and the United States: the MINAP/NICOR, SWEDEHEART/RIKS-HIA, and ACTION Registry-GWTG/NCDR registries. Int J Cardiol2014; 175: 240–247.
12.
FröbertOLagerqvistBOlivecronaGK, et al.TASTE Trial. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med2013; 369: 1587–1597.
13.
RydénLFerranniniGMellbinL. Risk factor reduction in type 2 diabetes demands a multifactorial approach. Eur J Prev Cardiol2019; 26(2-suppl): 81–91.
